SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

Ver/Abrir
Identificadores
URI: https://hdl.handle.net/10902/34332
ISSN: 1699-048X
ISSN: 1699-3055
Compartir
Estadísticas
Ver Estadísticas
Google Scholar
Registro completo
Mostrar el registro completo DC
Autoría
López López, CarlosAutoridad Unican; Calvo, Mariona; Cámara, Juan Carlos; García-Paredes, Beatriz; Gómez-Martín, Carlos; López, Ana María; Pazo-Cid, Roberto; Sastre, Javier; Yaya, Ricardo; Feliu, Jaime
Fecha
2024
Derechos
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Publicado en
Clinical and Translational Oncology, 2024, 26, 2800-2811
Editorial
Springer-Verlag Italia
Palabras clave
Hepatocellular carcinoma
Guidelines
Diagnostic
Staging
Treatment
Resumen/Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.
Colecciones a las que pertenece
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.Excepto si se señala otra cosa, la licencia del ítem se describe como This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.